Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance)-Reference-Cited by-同舟云学术

Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance)

Published:2018-07-20 Issue:14 Volume:2 Page:1705-1718
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Byrd John C.¹,Ruppert Amy S.¹²,Heerema Nyla A.³,Halvorson Alese E.⁴,Hoke Eva⁵,Smith Mitchell R.⁶,Godwin John E.⁷,Couban Stephen⁸,Fehniger Todd A.⁹,Thirman Michael J.¹⁰,Tallman Martin S.¹¹,Appelbaum Frederick R.¹²,Stone Richard M.¹³,Robinson Sue⁸,Chang Julie E.¹⁴,Mandrekar Sumithra J.⁴,Larson Richard A.¹⁰

Affiliation:

1. Division of Hematology,

2. Alliance Statistics and Data Center, and

3. Department of Pathology, The Ohio State University, Columbus, OH;

4. Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN;

5. Alliance Statistics and Data Center, Duke University, Durham, NC;

6. Department of Medical Oncology and Hematology, George Washington University Cancer Center, Washington, DC;

7. Providence Cancer Center, Portland, OR;

8. QEII Health Sciences Centre, Halifax, NS, Canada;

9. Division of Oncology, Washington University School of Medicine, St. Louis, MO;

10. Department of Medicine, University of Chicago Comprehensive Cancer Center, Chicago, IL;

11. Memorial Sloan Kettering Cancer Center, New York, NY;

12. Fred Hutchinson Cancer Research Center, Seattle, WA;

13. Dana-Farber/Partners CancerCare, Harvard Cancer Center, Boston, MA; and

14. Department of Medicine, University of Wisconsin, Madison, WI

Abstract

Key Points Brief lenalidomide consolidation after chemoimmunotherapy is acceptably tolerated and extends PFS and OS in CLL. FCR has superior efficacy compared with FR chemoimmunotherapy for CLL.

Publisher

American Society of Hematology

Subject

Hematology

Link

http://ashpublications.org/bloodadvances/article-pdf/2/14/1705/881002/advances015396.pdf

Reference48 articles.

1. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia;Hamblin;Blood,1999

2. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia;Damle;Blood,1999

3. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia;Orchard;Lancet,2004

4. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia;Rassenti;N Engl J Med,2004

5. Mutations driving CLL and their evolution in progression and relapse;Landau;Nature,2015

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Maintenance low-dose fixed duration lenalidomide and rituximab following bendamustine and rituximab induction in previously untreated chronic lymphocytic leukemia and small lymphocytic lymphoma;Leukemia & Lymphoma;2024-06-10

2. Maintenance therapy for chronic lymphocytic leukaemia;Cochrane Database of Systematic Reviews;2024-01-04

3. Second primary malignancies in patients with haematological cancers treated with lenalidomide: a systematic review and meta-analysis;The Lancet Haematology;2022-12

4. Leukemia-initiating HSCs in chronic lymphocytic leukemia reveal clonal leukemogenesis and differential drug sensitivity;Cell Reports;2022-07

5. Effect of Lenalidomide Maintenance in Chronic Lymphocytic Leukemia: A Meta-Analysis and Trial-Sequential Analysis;Current Oncology;2022-06-14